AIMP1 Protein May Be Promising Biomarker for NMOSD, Study Shows

People with neuromyelitis optica spectrum disorder (NMOSD) have elevated levels of the pro-inflammatory protein AIMP1 in the bloodstream, and higher levels seem to correlate with worse disability, a study showed. These AIMP1 levels dropped markedly after anti-inflammatory therapy, but still remained higher among patients in remission than in people…

Case Report Describes NMOSD Rebound During Pregnancy

A young woman had a rebound of neuromyelitis optica spectrum disorder (NMOSD) toward the end of her pregnancy, for which she underwent plasma exchange and took steroids, according to a report from researchers in the U.S. Because treatment with plasma exchange and steroids did not work well enough, the…

Rituximab Helps Ease Disability in Children With NMOSD, Study Finds

Rituximab may be effective for improving functionality in children with neuromyelitis optica spectrum disorder (NMOSD) or other inflammatory neurological disorders, though more research is needed to identify optimal treatment regimens, a new study reports. “Efficacy of [rituximab] in specific indications and good tolerance are confirmed in pediatric neurology.